Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2008.090019PMID 18593759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis

  2010cited by this paper
• Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

  2010cited by this paper
• Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment

  2010cited by this paper
• Treating rheumatoid arthritis to target: recommendations of an international task force

  2010cited by this paper
• Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study

  2010cited by this paper
• Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

  2010cited by this paper
• The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

  2010cited by this paper
• Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

  2010cited by this paper
• Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008

  2009cited by this paper
• A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools

  2009cited by this paper
• Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis

  2009cited by this paper
• The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy

  2009cited by this paper
• Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

  2009cited by this paper
• Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

  2009cited by this paper
• Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease

  2009cited by this paper
• Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

  2009cited by this paper
• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

  2009cited by this paper
• No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort

  2009cited by this paper
• Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe

  2009cited by this paper
• Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population

  2009cited by this paper
• Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage

  2009cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cited by this paper
• Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

  2009cited by this paper
• Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA–WIS)

  2008cited by this paper
• Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

  2008cited by this paper
• Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence

  2008cited by this paper
• MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib

  2008cited by this paper
• The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus

  2008cited by this paper
• Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

  2008cited by this paper
• The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

  2007cited by this paper
• Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.

  2007cited by this paper
• Assessing remission in clinical practice.

  2007cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

  2007cited by this paper
• Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.

  2007cited by this paper
• Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

  2006cited by this paper
• Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.

  2006cited by this paper
• Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.

  2006cited by this paper
• The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey.

  2006cited by this paper
• Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.

  2006cited by this paper
• Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

  2005cited by this paper
• Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

  2005cited by this paper
• Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

  2005cited by this paper
• The British Society for Rheumatology Biologics Register

  2005cited by this paper
• Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

  2005cited by this paper
• Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?

  2005cited by this paper
• Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

  2004cited by this paper
• The use of TNF-α blocking agents in rheumatoid arthritis: an overview

  2004cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis.

  2000cited by this paper
• The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients.

  1998cited by this paper
• Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system.

  1997cited by this paper
• Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation

  1997cited by this paper
• Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

  1996cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• Interrelationship of outcome measures and process variables in early rheumatoid arthritis.

  1995cited by this paper
• Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

  1994cited by this paper
• [Results of a survey].

  1955cited by this paper
• Extended Report

  year unknowncited by this paper
• Extended Report

  year unknowncited by this paper
• Extended Report

  year unknowncited by this paper
• Extended Report

  year unknowncited by this paper

• Sulfated chitosan mitigates acute lung injury induced bone loss via immunoregulation

  2026cites this paper
• Biphasic bone loss in experimental autoimmune encephalomyelitis.

  2025cites this paper
• Asthma remission in the context of other immune-mediated diseases.

  2025cites this paper
• Poor prognostic factors and unmet needs in rheumatoid arthritis

  2025cites this paper
• Adding ultrasound to treat-to-target shows no benefit in achieving clinical remission nor in slowing radiographic progression in rheumatoid arthritis: results from a multicenter prospective cohort

  2024cites this paper
• Management strategies in rheumatoid arthritis

  2024cites this paper
• Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data

  2024cites this paper
• The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib

  2024cites this paper
• Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity

  2024cites this paper
• Comparison of Remission Criteria in Patients with Rheumatoid Arthritis: Results from a Smart System of Disease Management Group

  2024cites this paper
• 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs

  2024influential citation
• Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).

  2023cites this paper
• Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM.

  2023cites this paper
• The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis

  2023cites this paper
• Definition of rheumatoid arthritis flare based on SDAI and CDAI

  2023cites this paper
• Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

  2023cites this paper
• A Clinical Review of Structural Damage in Psoriatic Arthritis for Dermatologists: From Pathogenesis to Ongoing Controversies.

  2023cites this paper
• A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

  2023cites this paper
• The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study

  2023cites this paper
• Examining Rehabilitation Dose in Adults With Rheumatoid Arthritis: Association With Baseline Factors and Change in Clinical Outcomes

  2022cites this paper
• Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

  2022cites this paper
• Investigation of remission with ultrasound in patients with rheumatoid arthritis according to different clinical remission criteria

  2022cites this paper
• Number Needed to Treat and Cost Per Responder of Janus Kinase Inhibitors Approved for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Japan.

  2022cites this paper
• Targeted therapy for autoimmune diseases based on multifunctional frame nucleic acid system: blocking TNF-α-NF-κB signaling and mediating macrophage polarization

  2022cites this paper
• Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study

  2022cites this paper
• Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

  2021cites this paper
• Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study

  2021cites this paper
• The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients

  2021cites this paper
• Development of an Educational Video for Self-Assessment of Patients with RA: Steps, Challenges, and Responses

  2021cites this paper
• SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters

  2021cites this paper
• SARS-CoV-2 infection induces in ammatory bone loss in golden Syrian hamsters

  2021cites this paper
• Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3

  2021cites this paper
• Application of Propolis in Protecting Skeletal and Periodontal Health—A Systematic Review

  2021cites this paper
• Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

  2020cites this paper
• Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al

  2020cites this paper
• Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis

  2020cites this paper
• Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat‐to‐Target Strategies

  2020cites this paper
• The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

  2020cites this paper
• Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.

  2020cites this paper
• Measures of Rheumatoid Arthritis Disease Activity

  2020cites this paper
• Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

  2020cites this paper
• Maintenance to target was associated with radiological outcomes in patients with rheumatoid arthritis: a real-world observational cohort study

  2020cites this paper
• Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis

  2020cites this paper
• Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

  2020cites this paper
• Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents

  2020cites this paper
• Contributing factors of clinical outcomes at 1 year post-diagnosis in early rheumatoid arthritis patients with tightly controlled disease activity in clinical practice: a retrospective study

  2020cites this paper
• Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients

  2020cites this paper
• Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity

  2019cites this paper
• Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis

  2019cites this paper
• Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis

  2019cites this paper
• Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.

  2019cites this paper
• Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis

  2019cites this paper
• Validité et reproductibilité de la thermographie par caméra thermique Flir One pour la mesure de l'activité rhumatoïde : étude pilote

  2019cites this paper
• Prospects for the Use of Gene Expression Analysis in Rheumatology

  2019cites this paper
• ACPA: anti-cyclic citrullinated peptide antibodies APRIL: proliferation-inducing ligand AS: ankylosing spondylitis ASICs: acid-sensing ion channels BLyS: B-lymphocyte stimulator CRP: C-reactive protein ECM: extracellular matrix ESR: erythrocyte sedimentation rate FKN: fractalkine IFN: interferon IL:

  2019cites this paper
• Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde

  2019cites this paper
• A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort.

  2019cites this paper
• Update of French society for rheumatology recommendations for managing rheumatoid arthritis.

  2019cites this paper
• Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice.

  2019cites this paper
• Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population

  2019cites this paper
• B 12 deficiency and other comorbid autoimmune diseases on treatment outcome in patients with rheumatoid arthritis : An exploratory cohort study

  2018cites this paper
• S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten

  2018cites this paper
• Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

  2018cites this paper
• Treating juvenile idiopathic arthritis to target: recommendations of an international task force

  2018cites this paper
• IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis

  2018cites this paper
• Dose optimisation of biologic dmards in rheumatoid arthritis. Long-term effects and possible predictors

  2018influential citation
• Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study

  2018cites this paper
• The influence of thyroid diseases, diabetes mellitus, primary hyperparathyroidism, vitamin B12 deficiency and other comorbid autoimmune diseases on treatment outcome in patients with rheumatoid arthritis

  2018cites this paper
• Discovery of circulating DMARD response biomarkers in rheumatoid arthritis

  2018influential citation
• [Upcoming value of gene expression analysis in rheumatology].

  2018cites this paper
• Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management

  2017cites this paper
• Rheumatology nurses : Adding value to arthritis care September 2017

  2017cites this paper
• Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28-CRP)

  2017cites this paper
• Évolution de la densité minérale osseuse au cours de la polyarthrite rhumatoïde sous biothérapie versus sans biothérapie, suivi à 8 ans

  2017cites this paper
• Patients with newly diagnosed rheumatoid arthritis are at increased risk of diabetes mellitus: an observational cohort study.

  2017cites this paper
• Defining and characterizing sustained remission in patients with rheumatoid arthritis

  2017cites this paper
• Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

  2017cites this paper
• Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

  2017cites this paper
• 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis

  2017cites this paper
• Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access

  2017cites this paper
• Syddansk Universitet Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus An Observational Cohort study

  2017cites this paper
• Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors

  2017cites this paper
• DAS 28-CRP ) An observational cohort study

  2017cites this paper
• What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

  2017cites this paper
• Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

  2017cites this paper
• Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy

  2017cites this paper
• Treat-to-target as an approach in inflammatory arthritis

  2016cites this paper
• Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

  2016cites this paper
• Subclinical ultrasound synovitis in a particular joint is associated with ultrasound evidence of bone erosions in that same joint in rheumatoid patients in clinical remission.

  2016cites this paper
• Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors

  2016cites this paper
• [Inflammation and bone : Osteoimmunological aspects].

  2016cites this paper
• Rheumatoid arthritis

  2016cites this paper
• Entzündung und Knochen

  2016cites this paper
• Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis

  2016cites this paper
• Metacarpophalangeal and wrist MRI bone marrow edema can reflect the disease activity of rheumatoid arthritis and correlate with SDAI, CDAI and DAS28.

  2016cites this paper
• Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate

  2016cites this paper
• Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data

  2015cites this paper
• [The Cutting-edge of Medicine; Progress and the issue toward the imaging of arthritis].

  2015cites this paper
• Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis

  2015cites this paper
• Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis

  2015cites this paper